

Università degli Studi di Catania

**Dipartimento di Medicina Clinica e
Sperimentale**

Dottorato di Ricerca in Biomedicina Traslazionale

XXX Ciclo

Rosalia Emma

**Evidence for enhanced oxidative stress in
smokers with severe asthma**

Tesi di Dottorato

Coordinatore: *Chiar.mo Prof. Lorenzo Malatino*

Tutor: *Chiar.mo Prof. Riccardo Polosa*

Anno Accademico 2016/2017

Index

Abbreviations.....	4
Abstract.....	5
1. Introduction.....	7
1.1 Definition and epidemiology of severe asthma.....	8
1.1.1 Prevalence of severe asthmatic smokers.....	12
1.2 Development of severe asthma in smokers.....	13
1.3 Clinical outcomes in smokers with severe asthma.....	15
1.4 Asthma and Smoking: biological mechanisms.....	19
1.4.1 Immunological phenotypes.....	19
1.4.2 Oxidative stress in asthmatic smokers.....	22
1.5 U-BIOPRED project.....	27
2. Aim of the Study.....	30
3. Methods.....	31
3.1 Patients.....	31
3.2 Protocol and sample collection.....	32
3.3 8-iso-PGF2 α assessment.....	33
3.4 Microarray assessment	34

3.5 Statistical analysis.....	37
4. Results.....	38
4.1 Clinical parameters.....	38
4.2 Lipid peroxidation in SAs/ex compared to SAn.....	43
4.3 mRNA-expression of pro-/anti-oxidant enzymes in induced sputum.....	45
4.4 mRNA-expression of pro-/anti-oxidant enzymes in bronchial biopsy.....	46
4.5 mRNA-expression of pro-/anti-oxidant enzymes in bronchial brushing.....	47
4.6 Correlation analysis.....	48
4.7 Fractional exhaled NO (FeNO).....	49
5. Discussion.....	51
5.1 Oxidative stress in severe asthmatic smokers/ex smokers vs non-smokers.....	51
5.2 Pro-oxidant enzymes.....	52
5.3 Anti-oxidant enzymes.....	55
5.4 Limitations of the study.....	57
6. Conclusions.....	60

Abbreviations

8-iso-PGF2 α : 8-Isoprostaglandin F2 α

BB: Bronchial Biopsy

BBr: Bronchial Brushing

CAT: catalase

CS: Cigarette Smoke

FC: Fold change

GPX1: glutathione peroxidase 1

IS: Induced Sputum

LOD: limit of detection

NOS: nitric oxide synthase

NOX2: NADPH oxidase 2

RNS: reactive nitrogen species

ROS: reactive oxygen species

SA: severe asthma/asthmatic

SAn: severe asthma non smokers

SAs/ex: severe asthma smokers/ex-smokers

SOD: superoxide dismutase

U-BIOPRED: Unbiased BIOMarkers for the PREDiction of
Respiratory Disease Outcomes

Abstract

Background

As part of the U-BIOPRED project, extensive clinical and biomarker information was collected from cohorts of adult severe asthma smokers/ex-smokers (SAs/ex) and severe asthmatic non-smokers (SAn). Oxidative stress in SAs/ex *vs.* SAn patients was investigated by analysing urinary 8-iso-PGF_{2α} and the mRNA expression of the main pro-oxidant (NOX2; NOSs) and anti-oxidant (SODs; CAT; GPX1) enzymes in the airways, in relation to clinical outcomes.

Methods

Urine and induced sputum (IS) were obtained from severe asthma patients. A bronchoscopy to obtain bronchial biopsy (BB) and brushing (BBr) was performed in a subset of patients. Urinary 8-iso-PGF_{2α} was quantified using mass spectrometry. IS, BB and BBr were processed for mRNA expression microarray analysis.

Results

Urinary 8-iso-PGF_{2α} was increased in SAs/ex compared to SAn ($p < 0.001$) and in current smokers vs ex-smokers and non-smokers ($p = 0.004$). Sputum mRNA expression of NOX2 were increased in SAs/ex compared to SAn (three probe-sets with $p < 0.05$). The mRNA expression of antioxidant enzymes was similar between the two severe asthma cohorts in all airway samples. NOS2 mRNA expression was decreased in BBr of SAs/ex compared to SAn ($p = 0.029$). NOS2 mRNA expression in BBr correlated with FeNO ($p < 0.001$). FeNO was lower in current-smokers than in ex-smokers ($p = 0.007$) indicating an effect of active smoking.

Conclusions

The data suggests evidence of greater systemic oxidative stress in SAs/ex with significant effects on the mRNA expression of NOX2 and NOS2 in the airways of severe asthmatic patients.

1. Introduction

Asthma is a life-long chronic inflammatory disease of the airways characterised by variable and recurring symptoms, airways hyperresponsiveness and airflow obstruction that is often reversible either spontaneously or with treatment. According to the World Health Organization (WHO), 235 million people suffer from asthma, but it is under-diagnosed and under-treated with substantial burden to individuals and families. It is a complex and heterogeneous disorder that vary in severity, onset, risk factors, triggers, response to treatments, genetics/epigenetics and natural history (1). The aetiology of asthma is not completely understood but it is know that a gene-environment interaction play an essential role (2). Cigarette smoke is a key factor implicated in modulation of asthma. Data on asthmatic smokers suggest marked impairment in asthma control, accelerated decline in lung function, increased airflow obstruction and increase in disease severity (3). The majority of asthmatics have a mild and controlled disease, whereas others exhibit a more severe condition with poor asthma control, frequent severe exacerbations and accelerated loss of lung function, despite intensive treatment.

Severe asthma is a serious health problem, which has been subject of intensive research over the last years. The Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) is one of the research projects with the aim of improving the management of severe asthma.

1.1 Definitions and Epidemiology of Severe Asthma

Severe asthma is a heterogeneous disease with varying in pathophysiological characteristics (4,5), and several definitions have taken place over the past decade [**Table. 1**].

The first definition were published in 1999 by European Respiratory Society (ERS) Task Force, which defined difficult asthma as “asthma remaining uncontrolled despite high dose inhaled corticosteroids (ICS) with or without systemic corticosteroids (OCS)”, and uncontrolled asthma as “persistent asthma symptoms or recurrent exacerbations”(6).

Table 1. Definitions of “severe asthma”(7)

<i>Organisation, year</i>	<i>Term</i>	<i>Definition</i>
ERS, 1999	Difficult asthma	Asthma remaining uncontrolled despite high-dose inhaled glucocorticosteroids with or without systemic glucocorticosteroids
ATS, 2000	Uncontrolled asthma	Persistent asthma symptoms or recurrent exacerbations. According to an ERS Task Force including criteria that specifies asthma control
	Severe refractory asthma	Addition of responsiveness to treatment and future risk as a marker for asthma control
WHO, 2010		
IMI, 2011	Poorly controlled asthma	Algorithm to distinguish difficult-to-control asthma from severe refractory asthma
ATS/ERS, 2014		Latest recommendations on the identification, evaluation and treatment of patients with severe refractory asthma

ERS: European Respiratory Society; ATS: American Thoracic Society; WHO: World Health Organization; IMI: Innovative Medicines Initiative.

A year later, the American Thoracic Society (ATS) defined refractory asthma on the base of two major criteria (continuous of high dose of ICS or OCS for >50% of the time during the previous year) with two out of seven minor criteria: requirement of additional controller medications, aspects of disease stability, exacerbations and lung function (8). In 2010, the World Health Organization (WHO) added the “responsiveness to treatment”

and “future risk” as indicators of asthma control. The WHO distinguished three type of severe asthma: 1) untreated severe asthma; 2) severe difficult-to-control asthma; 3) severe refractory asthma (9). One year later the Innovative Medicines Initiative (IMI) published an algorithm in order to distinguish difficult-to-control asthma from severe refractory asthma. This algorithm included factors that can make asthma difficult to control, such as non-adherence to treatment, inadequate inhalation technique, continuous exposure to environmental triggers and comorbidities. The latest definition of severe asthma was given by a task force of ERS and ATS in 2014: asthma which requires treatment with high dose inhaled corticosteroids (>1000 mcg of fluticasone equivalent) plus a second controller and/or systemic corticosteroids, to prevent it from becoming “uncontrolled” or which remains “uncontrolled” despite this therapy (10).

Given the different definitions of severe asthma, it has been hard to determine the prevalence. In literature, severe asthma prevalence has been estimated around 5-10% of the total asthma population (11,12). However, this is a rough estimate, which varies from country to country due to access to, quality of

healthcare and adherence to treatment prescription. According to recent estimates reported by ERS, severe asthma affects 1.5 million of people in Europe (13). A recent database analysis based on 2014 ERS/ATS guidelines was conducted in Israel, where severe asthma prevalence was 4.65% of all asthmatics, and 33% of these was uncontrolled severe asthma (14). In the Netherlands the 17.4% of the total asthmatic population had difficult to control asthma according to the IMI criteria, but only 3.6% of these patients were adherent to their high dose ICS prescription (15). Thus, this suggested that the prevalence of truly severe refractory asthma could be lower than estimated in the past years.

Severe asthma, despite represent a small percentage of asthma patients, is responsible for a large part of asthma-related costs. In UK, it is estimated that 50% of all annual healthcare asthma costs come from the most severe asthmatic population (16). But, the severe asthma burden goes far beyond the healthcare costs: severe asthmatics patients often experienced work-related disability (partial or total lost-day, early disability or permanent disability) with a substantial socio-economics impact (11,16).

1.1.1 Prevalence of severe asthma smokers

The WHO has estimated in 2015 that there are 1.1 billion of smokers worldwide. The prevalence of active smoking in adults with asthma is similar to the prevalence in the general population, and ranges from 20% to 35% (17). Moreover, 20-30% of asthmatic adults are ex-smokers (18,19). As stated above, severe asthma occurs in 5-10% of the asthmatic population, but the prevalence of severe asthma current and ex-smokers is difficult to estimate. Indeed in the past years, asthmatic patients with a smoking history are often excluded from studies of severe asthma, such as the US Severe Asthma Research Program (20) and the European Network for Understanding Mechanisms of Severe Asthma (21), where smokers with or more 5 pack years use were excluded. Otherwise some studies, including the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) (22), British Thoracic Society (BTS) Severe Asthma Registry (23) cohorts and U-BIOPRED research project (24), did not exclude heavier smokers. The first two study report figures of 6% and 4% for current smokers, respectively, suggesting that active smoking is lower in severe

asthmatics than in the general population (17,25). Instead, ex-smokers with asthma represent one third of patients with severe or difficult-to-treat asthma (22,23). This interesting data suggest that cigarette smoke could have a role in the progression of asthma disease.

1.2 Development of severe asthma in smokers

Epidemiological evidences about the association of active smoking and asthma development was observed in some (26–35), but not in all studies (36,37). Many studies lack consistency, due to cross-sectional and case-control design, self-reported measures or questionnaires, potential inaccuracy in asthma diagnosis, which provide significant bias (3). Nevertheless, the majority of studies suggested that cigarette smoke increase the risk of developing asthma. Rasmussen et al. investigated the development of asthma in asymptomatic teenagers over a 6 years period, and showed that active smoking was independently associated with asthma-like symptoms (OR= 2.1; 95% CI= 1.2-3.8), as well as atopy and bronchial hyperresponsiveness to methacholine (27). A strong association was also found between

smoking and the onset of asthma among non-atopic subjects (OR= 5.7; 95% CI=1.7-19.2) (26). Moreover, tobacco smoking is a risk factor for the development of asthma in the elderly (28). In non-asthmatic adult with established allergic rhinitis, smoking was significantly related to the asthma onset within a period of 10 years (OR= 2.98; 95% CI= 1.81-4.92) with a clear dose-response association (35). Furthermore, active smoking was shown to be a predictor of an accelerate decrease of FEV₁ in longitudinal studies of asthma population (38,39). The analysis of a well-characterised cohort of allergic rhinitis patients followed for 10 years, showed that smoking status and smoking duration are associated with greater severity of new-onset asthma, with a dose-response association (40). Guus et al. also showed that the number of pack years was the only independent predictor for the progression of asthma severity, with an OR of 1.4 (95% CI, 1.02-1.91) every 10 pack years smoked (41).

All these studies showed that a positive smoking history in adult subjects is predictive of new-onset asthma and increase of asthma severity, in a dose-dependent manner.

1.3 Clinical outcomes in smokers with severe asthma

Cigarette smoking interacts with asthma and induces important adverse effects on clinical, functional, prognostic and therapeutic outcomes (3). Adults and teens with asthma who are active smokers show more severe symptoms and worse quality of life compared to asthmatic non-smokers (40). Many studies have reported an accelerated decline in lung function and an increased severity of airflow obstruction in asthmatic who smoke (38,42). Moreover, asthmatic patients who smoke don't have a response to the beneficial effects of inhaled corticosteroids (ICS) or oral corticosteroids (OCS) in contrast to asthmatic who don't smoke (43–45). Asthmatic smokers or ex-smokers often require hospitalization and emergency room treatment. In these patients COPD (secondary to asthma) and rhinovirus infections are frequently diagnosed (46). The viral infections, associated to asthma and smoking are difficult to treat because tobacco smoke increases viral replication and suppresses the protective functions of airway epithelium, alveolar macrophages, dendritic cells, NK cells and adaptive immune mechanism (47).

Few studies investigated clinical and inflammatory characteristics in severe asthmatic smokers, until now (**Tab. 2**).

Thomson et al. studied the cigarette smoking effect on severe asthma (25). They compared patient characteristics, clinical outcomes, and biomarkers of inflammation in current smokers, ex-smokers, and never smokers within a group of 760 patients with severe asthma recruited from the British Thoracic Society Severe Asthma Registry in the UK. These researchers found that current smokers with severe asthma had worse clinical outcomes compared to never smokers and ex-smokers, such as higher Asthma Control Questionnaire (ACQ) score, implying poorer asthma control, and lower Asthma Quality of Life Questionnaire (AQLQ) score, more unscheduled health care visits, more rescue courses of oral steroids, and higher anxiety and depression scores. Severe asthmatic current smokers had reduced sputum eosinophils and lower FeNO when compared to never smokers, whereas ex-smokers had increased proportion of sputum neutrophils than never smoker, but a similar sputum eosinophils count and FeNO value. Both current and former smokers had

reduced blood specific allergy antibody levels to several common environmental allergens (25).

Table 2. Clinical and inflammatory outcomes of severe asthma smokers

Clinical outcomes

- Late onset of severe asthma (25,48,49)
- Poorer asthma control (25,49,50)
- Worse quality of life (25,48)
- More unscheduled health care visits (25,50)
- More emergency department visits (25)
- More rescue courses of OCS (25)
- Higher anxiety and depression scale scores (25)

Lung function

- Lower Kco values (25)
- Severe airflow obstruction (49)

Inflammatory outcomes

- Lower FeNO value (25,48)

FeNO: Fractional exhaled nitric oxide; Kco: transfer coefficient for carbon monoxide; OCS: oral corticosteroids.

An initial analysis of clinical and inflammatory characteristics of U-BIOPRED severe asthma non-smokers and smokers/ex-smokers cohorts identified few differences. The two severe asthma groups showed a similar percentage received OCS therapy and similar degree of airflow obstruction. A lower FeNO level was observed in the smokers/ex-smokers cohort. Moreover, they showed that asthma onset occurred on average 18 years later in smokers/ex-smokers with severe asthma and a positive correlation between AQLQ scores and the number of pack years (48). A further cluster analysis of asthma patients from the U-BIOPRED adult cohorts identified four distinct clusters, one of these linked to smoking history. This cluster was composed of overweight to obese, late-onset severe asthmatic smokers/ex-smokers, with relatively poor control, severe airflow obstruction (mean FEV1= 58.9% predicted), and highest sputum and blood eosinophils, with a lower proportion of atopic subjects than in the other clusters (49).

These findings showed that cigarette smoking impaired the quality of life of severe asthma subjects with worse symptoms

and health-care outcomes compared to never smokers with severe asthma.

1.4 Asthma and Smoking: biological mechanisms

The mechanisms accounting for the adverse effects of smoking in asthma have been studied over the last few years, but are not completely understood. Inflammation and oxidative stress, induced by smoking, seems to play an important role in the pathogenesis of severe asthma smokers.

1.4.1 Immunological phenotypes

It is known that cigarette smoking induces airway inflammation in non-asthmatic smokers (51–54), with increased T lymphocytes and macrophages in the airway wall, higher neutrophils count in the bronchial secretion, and infiltration of mononuclear cells and macrophages in airways (52). Moreover, increased number of eosinophils infiltrating the submucosa was found in the peripheral lung sections of smokers compared to non-smokers (55). There is now accumulating evidence that cigarette smoke/asthmatic inflammation interaction may induce important changes in the

asthma phenotype [Fig.1]. Some researchers reported a predominance of macrophages and neutrophils in mild asthma who smoke, likewise in early COPD (51,56,57) and reduced sputum eosinophil count both in mild (57) and severe asthmatic smokers (25) compared to mild and severe asthmatic non-smokers, respectively. Neutrophils contribute to mucous hypersecretion, which is an additional risk factor for the accelerated decline in FEV₁ (3). Metalloproteinases (MMPs) are also involved in the modulation of inflammation, repair, and remodelling processes, along with their intrinsic and tissue inhibitors (58). Elevated concentration of MMP-12 was found in sputum of asthmatic smokers, with a positively correlation to sputum neutrophil count, and an inversely correlation to lung function (59). Sputum MMP-9 activity/TIMP-1 and TIMP-2 ratios, and nasal epithelial MMP9/TIMP1 and MMP9/TIMP2 expression ratios were found reduced in asthmatic smokers compared to never smokers. Furthermore, the low sputum ratios in asthmatic smokers were associated with reduced post-bronchodilator FEV₁, FEV₁/FVC ratio and segmental airway lumen area (60). Persistent exposure to cigarette smoke may also

alter the Th1/Th2-cytokine and Th17-cytokines secretion, modifying the inflammatory response (3,51).




Figure 1. Inflammatory mechanisms for the mixed asthma-smoking phenotype. In allergic asthma, initial exposure(s) of antigen-presenting cells (APCs) to allergen mainly leads to the activation of allergen-specific T-helper Th2 cells and immunoglobulin IgE synthesis. Subsequent exposures to allergen cause inflammatory-cell recruitment (e.g. eosinophils) and activation (e.g. mast cells) and mediator release. Th1-cell responses might also be responsible for epithelial apoptosis and smooth-muscle cell activation. Regulatory T-cells (Treg) are involved in the suppression of Th2-cell responses in humans through the inhibitory cytokines interleukin (IL)-10 and transforming growth factor (TGF)- β . The newly identified CD4⁺ T-cell subset, Th17 cells, seems to be specifically associated with the neutrophilic inflammatory events that occur during disease exacerbation and in tissue remodelling. Activated macrophages (AMs), triggered by cigarette smoke, will produce a myriad of pro-inflammatory molecules, reactive oxygen species (ROS), matrix metalloproteinase (MMPs), and chemokines involved in the mobilisation and prolonged survival of neutrophils in the lung tissue (e.g. IL-8). AMs in the smokers appear to produce less IL-10, which leads to less Th2-cells development and reduced B-cell number and lower levels of IL-4 and IL-5. This will produce fewer and less active eosinophils and lower production of IgE in smoking asthmatics. AMs are also involved in the direct stimulation of Th1 and Th17 cells that in turn promote bronchial epithelial cells and goblet cell activation to increase inflammatory responses, mucous production and tissue remodelling. Cigarette smoke might also directly activate bronchial epithelial cells to release further pro-inflammatory cytokines, chemokines, growth factors and TGF- β , which are known to modulate smooth muscle cell and fibroblast proliferation with subsequent progression to fibrosis and extracellular matrix deposition. In smoking, asthma-increased levels of thymic stromal lymphopoietin may further stimulate mast cells to release remodelling mediators, such as IL-13, independently of Th2 cells. Increased MCs, together with smoking-induced epithelial cell activation, may increase IL-8 production, contributing to further infiltration of neutrophils. Neutrophil infiltration favours the progression of the inflammatory response and lung damage of the smoker through the production of ROS, lipid mediators and tissue proteases. The persistent exposure to cigarette smoke drives additive or synergistic inflammatory and remodelling responses (e.g. chronic mucus hypersecretion) in the asthmatic airways (3). LTB₄: leukotriene B₄; GM-CSF: granulocyte-macrophage colony-stimulating factor; MHC: major histocompatibility complex; TCR: T-cell receptor; TNF- α : tumour necrosis factor- α ; IFN- γ : interferon- γ ; LTs: leukotrienes; PGs: prostaglandins (Polosa et al. Eur Respir J. 2013).

The recent severe asthma smokers/ex-smokers phenotype, identified by U-BIOPRED investigators, had a high sputum and blood eosinophil count and a differential transcript expression profile in sputum cells related to the regulation of actin cytoskeleton (ITGB1, ITGB8, FN1, DIAPH2, F2R, 332 ACTN2), and to fibronectin matrix formation (ITGB1, FN1) (49). These findings give a further confirmation of the cigarette smoke effect in severe asthma.


1.4.2 Oxidative stress in asthmatic smokers

“Oxidative stress” describes the level of oxidative damage in cells, tissues or organs, caused by reactive chemical species, derived from oxygen or nitrogen, such as reactive oxygen species (ROS) or reactive nitrogen species (RSN), respectively. ROS/RSN are oxidant metabolites that have the ability to snatch electrons from other molecules which come in contact with them (61). The sources of ROS/RSN can be exogenous, primarily tobacco smoke and air pollution, and endogenous, such as chemical reactions that occur in physiological or pathological conditions (62,63). Tobacco smoke is one of major source of oxidative stress: a single puff of smoke contain $>10^{15}$

oxidants/free radicals (64). These reactive chemical species have a physiologic function, as signalling molecules, at low concentrations, but at high concentration, they are harmful to cells (61). Due to high risk of exposure to a number of oxidizing substances, the human body has developed a wide range of enzymatic and non-enzymatic antioxidant defences (65). The oxidative stress is particularly enhanced in chronic inflammatory conditions, such as chronic asthma, characterized by raised ROS/RSN generation at the site of inflammation (61). Furthermore increased levels of ROS/RSN promote the inflammatory responses (62) triggering a chain of events that lead to the maintenance and worsening of pathological conditions, such as in asthma.

The airways are normally exposed to environmental oxidative compounds, moreover in asthma patients the conditions are worsened by the persistence of activated inflammatory cells in lung parenchyma. The activation of inflammatory cells leads to production of anion superoxide ($O_2^{\bullet-}$) and nitric oxide (NO). The anion superoxide is produced through the NADPH oxidases

(NOXs) pathway that are enzymes catalyzing the production of $O_2^{\bullet-}$ by reducing oxygen, using NADPH as electron donor (66):



NOXs enzymes are expressed in a number of lung cell types, as well as epithelial, endothelial and mesenchymal cells (67). The NOX2 isoform, in particular, is referred to “phagocyte NOX”. Indeed, it is primarily present in macrophages, neutrophils and eosinophils, and its activity is normally required for phagocyte respiratory burst and regulation of cell signaling (66,67). The $O_2^{\bullet-}$, produced by NOXs, is quickly converted to hydrogen peroxide (H_2O_2) by superoxide dismutase enzymes (SOD) (68). There are three forms of SOD, present in all classes of lung cells with different expression and localization. The cytosolic SOD (SOD1; CuZnSOD) and the mitochondrial SOD (SOD2; MnSOD) are expressed in human bronchial epithelial cells and in alveolar macrophages. While, the extracellular SOD (SOD3; ECSOD) is expressed in the pulmonary vasculature and interstitium (69,70). H_2O_2 is not a free radical, but it is, at least, a reactive chemical specie. For this reason, it is transformed in H_2O by two antioxidant enzymes: catalase (CAT) and glutathione

peroxidase (GPX) (64). CAT is localized in peroxisomes and cytoplasm of alveolar type II pneumocytes, macrophages and neutrophils (64,65). GPX family comprises 8 enzymatic isoforms and their expression levels vary depending on the tissue type. The most abundant isoform is the glutathione peroxidase 1(GPX1) (71). The H_2O_2 , not converted in H_2O , can react with transition metals to generate hydroxyl radicals ($\bullet OH$) or interacts with halides to form hypobromous acid (HOBr) or hypochlorous acid (HOCl), that are reactive compounds too (68). Nitric oxide (NO) is the other free radical produced by activated inflammatory cells through the degradation of L-arginine to L-citrulline by nitric oxide synthase (NOS) enzymes (72,73):



There are three isoforms of NOS: NOS1 and NOS3 are classified as constitutive and calcium-dependent isoforms, whereas NOS2 (iNOS) is the inducible and calcium-independent isoform (74,75). The up-regulation of iNOS leads to increased levels of NO that, in the presence of ROS, rapidly forms RNS (68) [**Fig. 2**]. Excess ROS and RSN lead to peroxidation of membrane lipids, depletion

of nicotinamide nucleotides, enhanced intracellular Ca^{2+} , cytoskeleton breakage and DNA damage (64,68).




Figure 2. Generation of reactive species and antioxidant defences in the lung. $\text{O}_2\bullet^-$ = superoxide anion; H_2O_2 = hydrogen peroxide; HOBr = hypobromous acid; HOCl = hypochlorous acid; NO = nitric oxide; RSN = reactive nitrogen species; $\bullet\text{OH}$ = hydroxyl radical; Fe^{2+} = ferrous ion; NOX = NADPH oxidase; SOD = superoxide dismutase; GPX = glutathione peroxidase; CAT = catalase; iNOS = inducible nitric oxide synthase.

Tobacco smoke is a complex mixture of thousands of different chemical species, which can damage macromolecules and biochemical pathways. Consequently, the inhalation of cigarette smoke triggers many cellular and signaling responses that contribute to maintenance and progression of the inflammatory response and disease chronicity in asthma patients who smoke.

Many oxidant compounds (ROS and RNS, quinones, aldehydes, ketones, metals) are present in cigarette smoke (76,77). These molecules may induce direct or indirect oxidative damage, through the generation of pro-inflammatory compounds (chemokines, cytokines, prostaglandins, leukotrienes, isoprostanes) and the modulation of intracellular pro-inflammatory pathways (MAPK, NF- κ B, AP-1, Keap1-Nrf2-ARE) (62,76,78). Very little is known about the role of oxidative stress in severe refractory asthma and even less about the combined impact of cigarette smoking.

1.5 U-BIOPRED project

U-BIOPRED (79) is an European research project started in 2008 by the European Commission and the Innovative Medicines Initiative (IMI), using information and samples from adults and children to learn more about different types of asthma to ensure better diagnosis and treatment for each person.

To achieve their aim, the pan-European consortium U-BIOPRED used an innovative systems biology approach to integrate

unbiased high dimensional data obtained by different “omics” technologies from invasive and non-invasive sampling, together with clinical data. The ultimate outcome of the project is to advance the understanding of asthma and create a “handprint” of severe asthma.




Figure 3. U-BIOPRED Innovative approach to generate “phenotype handprint”.

U-BIOPRED has enrolled up to 500 adult asthmatic patients, 421 of which are severe asthmatics (severe asthma non-smokers: 311; severe asthma smokers/ex-smokers: 110).

The Polosa's team of University of Catania, together with the 11 European academic centers, has contributed to create a detailed clinical database of severe asthmatic patients, with and without a smoking history, and a biobank of their biologic samples. Thus, the U-BIOPRED database is a unique opportunity to learn more about severe asthmatic smokers.

2. Aim of the Study

We hypothesize that cigarette smoke increases airway inflammation not only by providing additional oxidant species, but also by modulating the anti-/pro-oxidant balance.

We therefore compared the oxidative stress status in SA patients with and without a significant smoking history. We investigated the level of the lipid peroxidation marker 8-iso-PGF_{2α} in the urine and the mRNA expression profile of key pro-oxidant (NADPH oxidase 2, NOX2; inducible NOS, NOS2; constitutive NOSs, NOS1 and NOS3) and anti-oxidant (superoxide dismutases, SOD1, -2 and -3; catalase, CAT; and glutathione peroxidase 1, GPX1) enzymes in the airways, in particular in bronchial biopsy (BB), bronchial brushing (BBr) and induced sputum (IS) samples.

3. Methods

3.1 Patients

Participants with severe asthma were recruited from 16 clinical centres in 11 European countries (48). Severe asthma was defined according to the U-BIOBRED international consensus criteria (80). Prior to enrolment, participants with severe asthma were required to have been under follow-up by a respiratory physician for at least six months, during which time assessments had been undertaken to optimize asthma control and assess medication adherence. The Severe Asthma U-BIOPRED patients were divided in two groups:

- *Severe non-smoking asthma (SAn)*: non-smokers and ex-smokers with a less than five pack-year smoking history, with asthma and uncontrolled symptoms defined according to GINA guidelines 22 and/or frequent exacerbations (more than two per year) despite high-dose inhaled corticosteroids ($\text{ICS} \geq 1000 \mu\text{g}$ fluticasone propionate/day or equivalent dose).

- *Smokers and ex-smokers with severe asthma (SAs/ex)*: this group was defined as for the SAn group except that they were either current smokers or ex-smokers with a pack history of at least five years.

The study was approved by the ethics committee for each participating clinical institution, and adhered to the standards set by International Conference on Harmonisation and Good Clinical Practice. It is registered on ClinicalTrials.gov, (Identifier: NCT01982162). All participants gave signed informed consent.

3.2 Protocol and sample collection

All enrolled subjects underwent a baseline visit to assess current health status, atopy and pulmonary function. Spirometry, reversibility test (post-bronchodilator) and fraction of exhaled nitric oxide level (FeNO) at 50 ml/sec were performed. Spirometry were performed according to current ATS/ERS guidelines (81,82). Allergic status was assessed by skin prick test and measurement of total and specific IgE to six common aeroallergens. Questionnaires were administered to assess asthma

control (ACQ), health outcomes (AQLQ and HADS), upper airways symptoms (SNOT20), adherence (MARS) and sleep and daytime drowsiness (ESS). Urine samples and induced sputum (IS) were collected during the baseline visit. Some patients underwent an optional bronchoscopy visit during which bronchial biopsy (BB) and bronchial brushing (BBr) were obtained.

3.3 8-iso-PGF2 α assessment

8-iso-PGF2 α was extracted from spot urine samples (SAn: 305; SAs/ex: 109) using solid phase extraction and quantified via liquid chromatography coupled to mass spectrometry (LC-MS/MS) using an Acquity UPLC coupled to a Xevo TQ-S mass spectrometer (Waters, Milford, MA). Optimal extraction volumes for solid phase extraction were calculated using individual UV absorbance ($\lambda=300$ nm) measurements to minimize matrix effects and levels of 8-iso-PGF2 α were normalized to urinary creatinine (83).

3.4 Microarray assessment

RNA from RNAlater-preserved IS, BB, and BBr samples were extracted using Qiagen miRNeasy kit and amplified with Nugen ovation pico WTA kit (NuGen Technologies; San Carlos, CA). The cDNA was analysed using the Affymetrix HG-U133+PM microarray platform (Affymetrix, Santa Clara, CA). CEL files were normalized, assessed for quality control to exclude technical outliers (chip image analysis, Affymetrix GeneChip QC, RNA degradation analysis, distribution analysis, principal components analysis, and correlation analysis), and re-normalized using the robust multi-array (RMA) method.

For IS, RNA was extracted from 362 samples, of which 228 had sufficient sample for microarray analysis. 15 of these samples failed QC metrics, 19 additional samples were excluded (not considered enrolled in adult cohorts), and 71 samples disqualified for squamous>30% or no differential counts available, with 123 quality samples remaining for subsequent analyses (SAn: 61; SAs/ex: 23; remainder were for non-severe asthmatics and healthy).

For BB, RNA was extracted from 116 samples and had sufficient sample for microarray analysis. Seven of these samples failed QC metrics, and 1 additional sample was excluded (not considered enrolled in adult cohorts), with 108 quality samples remaining for subsequent analyses (SAn: 40; SAs/ex: 13; remainder were for non-severe asthmatics and healthy).

For BBr, RNA was extracted from 159 samples, of which 158 had sufficient sample for microarray analysis. Six of these samples failed QC metrics, 3 additional samples were excluded (2 duplicate samples and 1 not considered enrolled in adult cohorts), with 149 quality samples remaining for subsequent analyses (SAn: 49; SAs/ex: 18; remainder were for non-severe asthmatics and healthy).

A log₂-intensity threshold was established as the limit of reliable quantification (LOD) based on the 90th percentile signal of merged nonspecific probe-sets distribution in the array and by the inflection point of maximum variance with decreasing signal in a standard deviation vs. mean intensity plot across all probe sets. Probe sets with mean log₂ intensity above this threshold in at least one of the 4 study cohorts were considered quantifiable and

included in subsequent analyses. The cut-offs (number of probe sets included) were 5.5 (23496), 5.0 (18697), and 4.75 (21363) for sputum, BB, and BBr, respectively.

Batch effects from RNA processing sets were observed for the sputum and BBr datasets, with the batch effect adjusted in the data matrices using linear modelling of batch (as random factor) and cohort. For the sputum dataset, 3 subjects had duplicate samples, of which the mean of the log₂ intensities, after RNA processing set batch adjustment, were used in the final analysis dataset.

The probe-sets used in this study were as follow: NOX2 (203922_PM_s_at, 203923_PM_s_at, 217431_PM_x_at, 233538_PM_s_at); NOS1 (1560974_PM_s_at, 207309_PM_at, 207310_PM_s_at, 231916_PM_at, 239132_PM_at, 240911_PM_at); NOS2 (210037_PM_s_at); NOS3 (205581_PM_s_at); SOD1 (200642_PM_at); SOD2 (215078_PM_at, 215223_PM_s_at, 216841_PM_s_at, 221477_PM_s_at); SOD3 (205236_PM_x_at); CAT (201432_PM_at, 211922_PM_s_at, 215573_PM_at); GPX1 (200736_PM_s_at).

3.5 Statistical analysis

Categorical data were summarized by counts and percentages; continuously distributed data, exhibiting approximate symmetry of distribution, were summarized using the mean (standard error; SE); continuously distributed data exhibiting skewness were summarized using the median (inter-quartile range; IQR). The latter all exhibited positive skewness and were log-transformed prior to parametric association testing. P-values were calculated by applying ANOVA to a generalised linear model with adjustment for age and gender. All analyses were considered significant with a p-value of less than 5 %. Acknowledging the modest sample size of the current exploratory study, adjustments for multiple-testing were not applied. In order to characterise further some of the observed associations, rank correlation was assessed by calculation of Kendall's Tau. A p-value was calculated in a test of the null hypothesis of zero correlation. Analyses of clinical and inflammatory data were performed using R version 2.15.2 (R Core Team, 2012).

4. Results

4.1 Clinical parameters

The clinical and inflammatory characteristics of severe asthma patients (SAn and SAs/ex) are reported in **Tables 3-7** for each examined patient subset (urine-lipidomics; IS-transcriptomics; BB-transcriptomics; BBr-transcriptomics). In brief, spirometry parameters were similar among SAn and SAs/ex. The onset of asthma occurred 17 years later in SAs/ex than in SAn although subjects had a similar degree of airway obstruction. Moreover SAs/ex had increased prevalence of gastro-esophageal reflux disease (GERD) than SAn. FeNO levels were significantly lower in SAs/ex than SAn for those subjects for whom BB and BBr transcriptomics data was available but this was not seen across all subgroups (data not show).

Table 4. Clinical and inflammatory characteristics of severe asthma patients present in the urinary eicosanoids subset.

	SAn	SAs/ex	p value
Subjects n.	302	109	
Age (yr)[#]	53 (43-62) [n=302]	55 (48-61) [n=109]	0.016
Female[§]	201/302 (65.9%)	56/109 (51.38%)	0.008
Age at Diagnosis(yr) [#]	20.5 (7-38) [n=296]	37.50 (20-48) [n=108]	<0.001
Exacerbations (History) [#]	2 (1-3) [n=302]	2 (1-4) [n=109]	0.767
Pack Years[#]	2 (1-4) [n=45]	17.25 (10-26) [n=109]	<0.001
Allergic Rhinitis Diagnosed[§]	160/271 (59.04%)	44/100 (44%)	0.010
Nasal Polyps Diagnosed[§]	100/286 (34.97%)	34/100 (34%)	0.861
GERD Diagnosed[§]	133/283 (47%)	62/98 (63.27%)	0.006
FEV₁ % pred[*]	67.28±1.28 [n=302]	67.39±1.85 [n=109]	0.647
FVC % pred[*]	87.19±1.13 [n=302]	89.89±1.74 [n=109]	0.163
FEV₁/FVC ratio[*]	0.64±0.01 [n=302]	0.61±0.01 [n=109]	0.098
Exhaled NO[#]	26.50 (16-47) [n=284]	23.00 (12-43) [n=103]	0.091
Sputum Eosinophils[#]	14.00 (2-85) [n=128]	21.00 (4-70) [n=53]	0.680
Sputum Neutrophils[#]	274 (169-402) [n=128]	296 (199-354) [53]	0.346
Sputum Eosinophils (%)[#]	2.75 (0-19) [n=128]	4.13 (1-14) [n=53]	0.959
Sputum Neutrophils (%)[#]	53.69 (34-75) [n=128]	55.15 (35-65) [n=53]	0.433
Mean ACQ with ACQ7[#]	2.71 (2-4) [n=274]	2.57 (2-3) [n=95]	0.951
Regular ICS or ICS/LABA Use[§]	301/302 (99.67%)	109/109 (100%)	0.997
Regular Oral Corticosteroids[§]	133/291 (45.7%)	45/102 (44.12%)	0.782

Data are presented as *mean±SE, [#]median (interquartile range) [n] or [§]n/N (%), unless otherwise stated. GERD: gastro-esophageal reflux disease; FEV₁: forced expiratory volume in one second; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroids; LABA: long-acting β₂-agonist.

Table 5. Clinical and inflammatory characteristics of severe asthma patients present in the induced sputum-transcriptomics subset.

	SAn	SAs/ex	p value
Subjects n.	61	23	
Age (yr)[#]	55 (46-62) [n=61]	54 (46-56) [n=23]	0.797
Female[§]	37/61 (60.66%)	12/23 (52.17%)	0.483
Age at Diagnosis(yr)[#]	22 (6-38) [n= 60]	39 (20-50) [n=23]	0.031
Exacerbations (History)[#]	2 (1-3) [n=61]	2 (0-3) [n=23]	0.575
Pack Years[#]	1.50 (1-3) [n=14]	16 (12-25) [n=23]	<0.001
Allergic Rhinitis Diagnosed[§]	24/53 (45.28%)	7/21 (33.33%)	0.350
Nasal Polyps Diagnosed[§]	22/59 (37.29%)	8/22 (36.36%)	0.939
GERD Diagnosed[§]	25/58 (43.1%)	13/21 (61.9%)	0.144
FEV₁ % pred[*]	61.25±2.77[n=61]	67.74±3.61 [n=23]	0.129
FVC % pred[*]	87.25±2.37[n=61]	94.69±3.91 [n=23]	0.111
FEV₁/FVC ratio[*]	0.57±0.02 [n=61]	0.59±0.02 [n=23]	0.560
Exhaled NO[#]	24.50 (16-46) [n=59]	28.50 (10-50) [n=22]	0.393
Sputum Eosinophils[#]	14 (2-82) [n=61]	36 (6-84) [n=23]	0.304
Sputum Neutrophils[#]	312 (222-442) [n=61]	296 (236-370) [n=23]	0.754
Sputum Eosinophils (%)[#]	2.70 (0-16) [n=61]	7.06 (1-16) [n=23]	0.384
Sputum Neutrophils (%)[#]	66.12 (45-84) [n=61]	55.15 (45-66) [n=23]	0.906
Mean ACQ with ACQ7[#]	2.43 (2-4) [n=57]	2.21 (2-3) [n=20]	0.767
Regular ICS or ICS/LABA Use[§]	61/61 (100%)	23/23 (100%)	1.000
Regular Oral Corticosteroids[§]	25/59 (42.37%)	13/21 (61.90%)	0.128

Data are presented as *mean±SE, [#]median (interquartile range) [n] or [§]n/N (%), unless otherwise stated.

GERD: gastro-esophageal reflux disease; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroids; LABA: long-acting β₂-agonist.

Table 6. Clinical and inflammatory characteristics of patients present in Bronchial Biopsy-transcriptomics subset.

	SAn	SAs/ex	p value
Subjects n.	40	13	
Age (yr)[#]	51 (40-60) [n=40]	55 (52-56) [n=13]	0.152
Female[§]	23/40 (57.5%)	5/13 (38.46%)	0.237
Age at Diagnosis(yr)[#]	9 (2-38) [n=39]	33 (7-45) [n=13]	0.227
Exacerbations (History)[#]	2 (1-4) [n=39]	3 (1-4) [n=13]	0.362
Pack Years[#]	1.75 (1-3) [n=6]	22.50 (18-33) [n=13]	<0.001
Allergic Rhinitis Diagnosed[§]	23/37 (62.16%)	4/13 (30.77%)	0.058
Nasal Polyps Diagnosed[§]	14/38 (36.84%)	5/13 (38.46%)	0.917
GERD Diagnosed[§]	21/39 (53.85%)	8/12 (66.67%)	0.436
FEV₁ % pred*	72.19±3.25 [n=40]	68.74±4.16 [n=13]	0.716
FVC % pred*	90.04±2.81 [n=40]	93.98±2.33 [n=13]	0.336
FEV₁/FVC ratio*	0.67±0.02 [n=40]	0.60±0.03 [n=13]	0.074
Exhaled NO[#]	30 (20-46) [n=35]	19 (8-24) [n=13]	0.017
Sputum Eosinophils[#]	14.50 (3-72) [n=22]	6.50 (2-14) [n=4]	0.337
Sputum Neutrophils[#]	267.50 (215-351)[n=22]	260.00 (154-347) [n=4]	0.091
Sputum Eosinophils (%)[#]	2.70 (1-14) [n=22]	1.30 (0-3) [n=4]	0.321
Sputum Neutrophils (%)[#]	51.47 (41-66) [n=22]	49.23 (27-69) [n=4]	0.101
Mean ACQ with ACQ7[#]	2 (1-3) [n=34]	2.79 (2-4) [n=10]	0.247
Regular ICS or ICS/LABA Use[§]	40/40 (100%)	13/13 (100%)	1.000
Regular Oral Corticosteroids[§]	17/37 (45.95%)	5/13 (38.46%)	0.641

Data are presented as *mean±SE, [#]median (interquartile range) [n] or [§]n/N (%), unless otherwise stated. GERD: gastro-esophageal reflux disease; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroids; LABA: long-acting β₂-agonist.

Table 7. Clinical and inflammatory characteristics of severe asthma patients present in Bronchial Brushings-transcriptomics subset.

	SAn	SAs/ex	p value
Subjects n.	49	18	
Age (yr)[#]	51 (38-60) [n=49]	53 (48-55) [n=18]	0.227
Female[§]	25/49 (51.02%)	7/18 (38.89%)	0.380
Age at Diagnosis(yr)[#]	15 (4-38) [n=47]	31.5 (16-44) [n=18]	0.165
Exacerbations (History)[#]	2 (1-3) [n=48]	2 (1-4) [n=18]	0.804
Pack Years[#]	2 (2-4) [n=9]	20.25 (16-37) [n=18]	<0.001
Allergic Rhinitis Diagnosed[§]	27/44 (61.36%)	6/18 (33.33%)	0.049
Nasal Polyps Diagnosed[§]	18/44 (40.91%)	7/17 (41.18%)	0.985
GERD Diagnosed[§]	27/46 (58.7%)	11/17 (64.71%)	0.666
FEV₁ % pred[*]	75.78±2.4 [n=49]	66.24±3.53 [n=18]	0.134
FVC % pred[*]	91.92±1.93 [n=49]	90.11±2.61 [n=18]	0.842
FEV₁/FVC ratio[*]	0.68±0.02 [n=49]	0.60±0.02 [n=18]	0.027
Exhaled NO[#]	32.50 (19-56) [n=45]	20.00 (10-28) [n=17]	0.020
Sputum Eosinophils[#]	7.00 (2-82) [n=21]	3.00 (2-56) [n=7]	0.783
Sputum Neutrophils[#]	263 (214-420) [n=21]	244 (193-329) [n=7]	0.771
Sputum Eosinophils (%)[#]	1.44 (0-16) [n=21]	0.60 (0-10) [n=7]	0.754
Sputum Neutrophils (%)[#]	52.29 (40-71) [n=21]	43.65 (33-64) [n=7]	0.635
Mean ACQ with ACQ7[#]	2.00 (1-3) [n=39]	2.57 (2-4) [n=13]	0.330
Regular ICS or ICS/LABA Use[§]	49/49 (100%)	18/18 (100%)	1.000
Regular Oral Corticosteroids[§]	19/45 (42.22%)	9/17 (52.94%)	0.451

Data are presented as ^{*}mean±SE, [#]median (interquartile range)[n] or [§]n/N (%), unless otherwise stated. GERD: gastro-esophageal reflux disease; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroids; LABA: long-acting β₂-agonist.

4.2 Lipid peroxidation in SAs/ex compared to SAn.

We analysed 8-iso-PGF_{2α}, a specific biomarker of lipid peroxidation, in spot urine samples. The median (IQR) concentration of 8-iso-PGF_{2α} was significantly increased in the urine of SAs/ex compared to SAn, 31.7 (24.5-44.7) vs. 26.6 (19.6-36.6) ng/mmol creatinine respectively (FC= 1.19; *p*< 0.001) (**Fig. 4**), indicating an increased level of oxidative stress in asthmatic patients who smoke.




Figure 4. Comparison of 8-iso-PGF_{2α} in urine between SAn and SAs/ex. The marker of lipid peroxidation is increased in SAs/ex, median (IQR)= 31.7 (24.5-44.7) compared to SAn, median (IQR)= 26.6 (19.6-36.6).

Furthermore, we assessed 8-iso-PGF_{2α} taking into consideration three smoking subgroups (current-, ex-, non-smokers) within the two SA cohorts (SAn+SAs/ex). A significant difference was observed between the smoking subgroups ($p= 0.004$) with increased median (IQR) concentration of urinary 8-iso-PGF_{2α} in current-smokers, 34.25 (24.4-47.7), vs ex-smokers, 29.4 (22.3-40.5), and non-smokers, 26.5 (19.6-16.6) (**Fig. 5**).




Figure 5. Comparison of urinary 8-iso-PGF_{2α} between severe asthma (SA) smoking subgroups. The median (IQR) concentration was increased in current-smokers, 34.25 (24.4-47.7), vs ex-smokers, 29.4 (22.3-40.5), and non-smokers, 26.5 (19.6-16.6). SAn: Severe Asthma non smokers; SAs/ex: Severe Asthma smokers/ex-smokers.

4.3 mRNA-expression of pro-/anti-oxidant enzymes in induced sputum

Sputum mRNA levels of the pro-oxidant enzymes NOX2 and NOS3 were examined. NOS1 and NOS2 probe sets were excluded because their mRNA expression levels were below the LOD. The mRNA levels of NOX2 were increased in SAs/ex compared to SAn. In particular the probe sets 203922_PM_s_at (FC= 1.05 $p=$ 0.006), 203923_PM_s_at (FC =1.06; $p=$ 0.003), 233538_PM_s_at (FC =1.06; $p=$ 0.014) were over-expressed in SAs/ex. The NOX2 probe set 217431_PM_x_at showed log₂ intensity lower than the other probe sets but was not significantly different between SAn and SAs/ex (FC= 1.00; $p=$ 0.950). The expression of NOS3 mRNA in IS was similar between SAs/ex and SAn.

SOD3 was excluded in IS analyses because its mRNA levels were below the LOD. CAT mRNA levels were over-expressed in SAs/ex compared to SAn for the probe set 201432_PM_at (FC= 1.07; $p=$ 0.028) but the probe set 211922_PM_s_at do not show a significant difference ($p=$ 0.359). By contrast, mRNA expression

of SOD1, SOD2, SOD3 and GPX1 were not statistically different between SAn and SAs/ex (**Table 8**).

Table 8. Microarray data of pro-/anti-oxidant enzymes in induced sputum of severe asthma cohorts.

Gene symbol	Probe-set ID	SAn (n=61) Mean	SAs/ex (n=23) Mean	Fold Change	p value
NOX2	203922_PM_s_at	9.89	10.35	1.05	0.006
	203923_PM_s_at	9.03	9.59	1.06	0.003
	217431_PM_x_at	5.96	5.97	1	0.950
	233538_PM_s_at	6.57	6.96	1.06	0.014
NOS3	205581_PM_s_at	6.32	6.19	-1.02	0.115
SOD1	200642_PM_at	8.37	8.69	1.04	0.094
SOD2	215078_PM_at	9.93	9.62	-1.03	0.225
	215223_PM_s_at	11.65	11.46	-1.02	0.303
	216841_PM_s_at	11.40	11.20	-1.02	0.098
	221477_PM_s_at	11.26	10.99	-1.02	0.121
CAT	201432_PM_at	8.41	9.01	1.07	0.028
	211922_PM_s_at	7.81	7.97	1.02	0.359
GPX1	200736_PM_s_at	9.57	9.74	1.02	0.385

Probe-sets with log₂ intensity >5.5 are reported in table. SAn: severe asthma non-smokers; SAs/ex: severe asthma smokers/ex-smokers; NOX2: NADPH oxidase 2; NOS3: nitric oxide synthase 3; SOD1/2: superoxide dismutase 1/2; CAT: catalase; GPX1: glutathione peroxidase 1.

4.4 mRNA-expression of pro-/anti-oxidant enzymes in Bronchial Biopsy.

All of the pro-oxidant enzymes were excluded in BB analyses because their expression levels were below the limit of detection (LOD threshold= 5). The expression of all antioxidant enzymes in BB was similar among SAn and SAs/ex (**Table 9**).

Table 9. Microarray data of pro-/anti-oxidant enzymes in bronchial biopsies of severe asthma cohorts.

Gene symbol	Probe-set ID	SAn (n=40) Mean	SAs/ex (n=13) Mean	Fold Change	p value
SOD1	200642_PM_at	8.36	8.30	-1.01	0.253
SOD2	215223_PM_s_at	7.00	7.03	1.00	0.667
	216841_PM_s_at	6.35	6.10	-1.04	0.075
	221477_PM_s_at	6.28	6.11	-1.03	0.148
SOD3	205236_PM_x_at	6.77	7.07	1.04	0.161
CAT	201432_PM_at	6.84	6.89	1.01	0.941
	211922_PM_s_at	5.73	5.68	-1.01	0.558
GPX1	200736_PM_s_at	7.04	7.19	1.02	0.437

Probe-sets with log₂ intensity >5 are reported in table. SAn: severe asthma non-smokers; SAs/ex: severe asthma smokers/ex-smokers; SOD1/2/3: superoxide dismutase 1/2/3; CAT: catalase; GPX1: glutathione peroxidase 1.

4.5 mRNA-expression of pro-/anti-oxidant enzymes in Bronchial Brushing.

NOS2 mRNA levels were significantly decreased in SAs/ex compared to SAn (FC= -1.10; $p= 0.029$). NOS3 mRNA expression was similar between SAn and SAs/ex (FC= -1.01; $p= 0.310$). In addition, the mRNA expression levels of anti-oxidant enzymes were similar among the two study groups (**Table 10**). NOX2, NOS1 and SOD3 were excluded from the analysis because their mRNA expression levels were below the LOD.

Table 10. Microarray data of pro-/anti-oxidant enzymes in bronchial brushings of severe asthma cohorts.

Gene symbol	Probe set ID	SAn (n=49) Mean	SAs/ex (n=18) Mean	Fold Change	p value
NOS2	210037_PM_s_at	5.36	4.87	-1.10	0.029
NOS3	205581_PM_s_at	4.97	4.88	-1.02	0.310
SOD1	200642_PM_at	9.03	8.99	-1.00	0.802
SOD2	215223_PM_s_at	7.58	7.25	-1.05	0.176
	216841_PM_s_at	6.90	6.56	-1.05	0.165
	221477_PM_s_at	6.84	6.60	-1.04	0.206
CAT	201432_PM_at	7.47	7.39	-1.01	0.620
	211922_PM_s_at	6.20	6.24	1.01	0.681
GPX1	200736_PM_s_at	7.56	7.58	1.00	0.960

Probe-sets with log₂ intensity >4.5 are reported in table. SAn: severe asthma non-smokers; SAs/ex: severe asthma smokers/ex-smokers; NOS2/3: nitric oxide synthase 2/3; SOD1/2: superoxide dismutase 1/2; CAT: catalase; GPX1: glutathione peroxidase 1.

4.6 Correlation analyses

There was no correlation between NOX2 mRNA in sputum and 8-iso-PGF_{2α} in urine ($p > 0.10$). Instead, NOX2 in sputum correlated significantly with macrophage numbers ($p < 0.001$) and percentages ($p < 0.001$) but inversely with eosinophil ($p = 0.01$, $p = 0.008$) and neutrophil ($p = 0.014$, $p = 0.008$) numbers and percentages respectively. Moreover, a strong correlation between NOS2 in BBr and FeNO was observed with a Kendall's Tau= 0.535 ($p < 0.001$) (**Fig. 6**). The same correlation analysis was also performed by smoking status (non-smokers, ex-smokers, current smokers): we observed a significant correlation in 36 non-smokers (Kendall's Tau= 0.551; $p < 0.001$); in 20 ex-smokers

(Kendall's Tau= 0.394; $p= 0.085$); the number of current smokers was very low (only six) and no correlation analysis was possible.




Figure 6. Scatter plot of the relationship between NOS2 expression in bronchial brushing and FeNO. There is a strong correlation between the two variables (62 non missing value; Kendall's Tau= 0.535, $p < 0.001$). SAn: Severe Asthma non-smokers; SAs/ex: Severe Asthma smokers/ex-smokers.

4.7 Fractional exhaled NO (FeNO)

FeNO levels correlated with NOS2 mRNA expression in BBr. To determine whether the slightly lower FeNO in SAs/ex is an effect of current smoking, we assessed FeNO between the three separate

smoking phenotypes (current-smokers, ex-smokers and never-smokers). We observed a significant difference between the three subgroups ($p= 0.012$). In particular, FeNO levels were lower in SA current-smokers than SA ex-smokers ($p= 0.007$) and SA never-smokers ($p= 0.004$). In contrast, SA ex-smokers and SA never-smokers showed similar levels of FeNO ($p= 0.975$) (**Fig. 7**). Further stratification into subgroups based on oral steroid prescriptions did not alter our findings (data not shown).




Figure 7. FeNO analysis among the three Severe Asthma (SA) smoker subgroups. The median (IQR) are: SA current smokers= 16 (10-31) ppb; SA ex-smokers= 25 (15-48) ppb; SA never-smokers= 27 (16-48) ppb.

5. Discussion

Little work has been performed to date to define the ability of tobacco smoke to modulate the oxidative stress balance in the airways of SA patients. The main findings of this paper can be summarised as follows: (i) SAs/ex showed an increased oxidative stress compared to SAn evidenced by 8-iso-PGF_{2α} levels in urine; (ii) tobacco smoke was associated with increased NOX2 mRNA expression in induced sputum; (iii) the mRNA expression of inducible isoform of NOS (NOS2) in airways correlates with FeNO levels, and (iv) FeNO levels are inversely associated with active smoking.

5.1 Oxidative stress in severe asthmatic smokers/ex smokers vs. non-smokers

Oxidative stress is thought to play a critical role in the pathophysiology of SA (62). Tobacco smoke is one of the major environmental sources of oxidative stress, which can lead to greater lipid peroxidation as evidenced by the increased level of

urinary 8-iso-PGF_{2α} in SAs/ex, particularly in current smokers. This is in line with other studies that showed the ability of cigarette smoke to increase isoprostane levels (84,85). F2-isoprostanes have a potent smooth muscle and vascular constrictive action, which increases airway hyperresponsiveness and obstruction, and induces plasma exudation and inflammation (86). Indeed, 8-iso-PGF_{2α} levels are elevated as asthma severity increases (87) and further enhanced during acute exacerbations of asthma (88) and following allergen challenge in asthmatics (87).

5.2 Pro-oxidant enzymes

The NOX2 isoform (phagocyte NOX) is primarily present in macrophages, neutrophils and eosinophils and is most highly expressed in IS. NOX2 activity is normally required for phagocyte respiratory burst and regulation of cell signalling (66,67). Furthermore, the enzyme NOX2 is activated by cigarette smoke through the phosphorylation of c-Src, a tyrosine kinase protein (89) leading to a higher production of ROS (89,90). In our study, NOX2 mRNA is over-expressed in sputum of SAs/ex compared to SAn, supporting the hypothesis that exposure to

smoke in asthmatic subjects is able to amplify NOX2 mRNA expression with a consequent elevation of $O_2^{\bullet-}$ production. There was no correlation between the NOX2 over-expression in IS and 8-iso-PGF_{2α} in urine. In all likelihood, NOX2 is just one of the several factors contributing to the increase of oxidative stress. The positive correlation of NOX2 mRNA with macrophages and the inverse relationship with phagocytes may highlight the importance of distinct cellular phenotypes of these cells in regulating the inflammatory process in severe asthmatics who smoke (91,92). This area deserves further investigation.

NOS enzymes are important pro-oxidants that produce NO, an endogenous regulator involved in homeostatic and immunological functions with a role in asthma pathogenesis (73). NOS1 and NOS3 are the constitutive isoforms and are commonly expressed in non-immunological cells. But non-canonical expression patterns were found in some cases (75). We observed no differences in NOS3 mRNA expression between SAn and SAs/ex. This could indicate a lack of effect of cigarette smoke on NOS3. NOS2 is the inducible isoform (iNOS) that produces high levels of NO and its activity persists for many days after

induction (74,75) leading to cell death and tissue damage (74). This enzyme is mainly expressed in lung epithelium (75), so it is mainly detectable in BBr. NOS2 mRNA expression is induced by pro-inflammatory cytokines (73,93), and is increased in chronic asthma in proportion to the severity of the disease (94), and in particular it is increased by allergen provocation (95). In this study, NOS2 mRNA is under-expressed in BBr of SAs/ex. Some researchers have shown that NO generated by NOS2 is able to attenuate its own expression through the negative regulation of NF- κ B (96). Furthermore, we demonstrated a strong correlation between FeNO levels and BBr NOS2 mRNA expression in SA cohorts, as previously reported (97). Therefore, we hypothesise that active exposure to cigarette smoke can lead to inhibition of NOS2 mRNA expression in a negative feedback manner.

Evidence exists of lower FeNO levels in asthmatic smokers (98), particularly in asthmatic current smokers (25). Moreover, the analysis of clinical and inflammatory characteristics of the U-BIOPRED adult cohorts found lower FeNO levels in the SAs/ex cohort, indicating a possible effect of current smoking (48). Nevertheless, we did not observe a significant difference on

FeNO levels comparing only SAn vs SAs/ex ($p= 0.89$, data not shown). Therefore, we checked if there was a direct effect of active smoking on exhaled NO. The analysis of FeNO, in relation to the cigarette smoking status of patients (current-, ex- and never-smokers), showed decreased FeNO levels in current smokers confirming the effect of active smoking on exhaled NO. Cigarette smoke contains high levels of superoxide, which can rapidly react with NO, which may account for the reduced FeNO levels in the current smokers. Moreover the product of this reaction, peroxynitrite, is a very strong oxidant species (64,68,73). Thus, knowledge of current smoking status is important when using FeNO measurements in assessing asthma control and severity.

5.3 Anti-oxidant enzymes

SODs are the primary enzymes able to dismantle superoxide anion to form H_2O_2 (64). We observed no significant differences in SOD1, SOD2 and SOD3 mRNA expression in airways of SAn and SAs/ex. In the literature, there is some contradictory evidence about the SODs enzymes in relation to asthma and tobacco

smoke. Some studies report that SOD1 has low activity and expression in asthmatic airways (64,70). SOD2 also was found to be inactivated and down regulated in asthmatic patients (70,99,100). Furthermore, the expression of SOD3 seems to be decreased *in vitro* by TNF- α , TGF- β and IL1- α , while it is enhanced by IFN- γ (64,101). Cigarette smoke enhanced the expression (102) and activity (103) of SODs in rat airways. Conversely, the levels of SOD were found increased in blood and saliva of subjects who smoke (104), and prolonged cigarette smoke exposure was found to increase the mRNA level of SOD2 in human bronchial epithelial cells (105). Therefore, it is conceivable that whilst SOD mRNA expression is decreased in SA, smoking enhances SOD mRNA expression, resulting in a balance between the two actions and overall no difference between SAn and SAs/ex.

CAT and GPX1 are key antioxidant enzymes for the degradation of reactive H₂O₂ to H₂O and O₂. Catalase (protein and mRNA levels) were previously reported as decreased in the bronchiolar epithelium of smokers with COPD (106). Furthermore, the activity of CAT and GPX was previously found reduced in

asthmatic patients (64). In contrast, we observed no significant effects of smoking on CAT and GPX1 levels. Further studies are required to determine whether the decreased expression reported by Betsuyaku et al. (106) were a result of smoking or of COPD.

5.4 Limitations of the study

Due to the explorative nature of this study, there are several limitations. The major limitation is the absence of a healthy smoker and non-smokers control groups, which we cannot to establish for sure the influence of cigarette smoking and/or severe asthma. However, our purpose was to explore the CS effect in patients with the same severity degree of asthma, assuming that the observed changes are predominantly due to smoking. Another limitation is that the measurement of whole body excretion of 8-iso-PGF_{2α} in urine cannot determine the source (airways or systemic source). Given that the patients in this study suffer from asthma, and with the observed relations to smoking, it is however likely that airways inflammation contributes the most to increased urinary excretion of 8-iso-PGF_{2α}; however, it would be of interest

to measure these effects in healthy smokers with normal lung function.

Few patients provided samples from each compartment within the U-BIOPRED study. Particularly, the number of SAs/ex samples is low for the sputum, BB and BBr transcriptomics set, thus we cannot divided SAs/ex group into current and ex-smokers for this subsets. Moreover, a negative result should be considered inconclusive. Due to the modest sample size of the current exploratory study, adjustments for multiple-testing were not applied. There is a good overlap, in term of patient coverage between BB, BBr and urine, and between sputum and urine. In contrast, there is little overlap between patients who had IS and BB/BBr.

We evaluated the mRNA expression of pro-/anti-oxidant enzymes, but the mRNA levels do not necessarily correlate with the production and activity of corresponding enzymes and proteins. Moreover, mRNA-expression of several enzymes could not be accurately assessed due to their low expression levels on the microarray. Although we report significant differences in oxidant gene expression of SAs/ex, the changes are small and

other mechanisms driving asthma severity in these patients may be present. Independent replications of these findings are warranted.

6. Conclusions

In conclusion, our results indicate that severe asthmatics who smoke have evidence for increased systemic oxidative stress. This may reflect the ability of smoking to increase the mRNA expression of NOX2 in the airways lumen without having a significant effect on anti-oxidant mRNA expression. Thus, there may be an imbalance between pro- and anti-oxidant enzymes in the SAs/ex group. Furthermore this is the first study showing a clear relationship between smoking, NOS2 and FeNO. Results on NOS2 and FeNO suggested a conceivable mechanism by which active CS may suppress the production of NO in the airways. Indeed, active smokers have a reduced level of FeNO, which is normalised in patients who quit smoking. Future studies are needed to investigate this complex mechanism in the framework of smoking related to severe asthma. Obviously, a program of smoking cessation should be considered for all severe asthma smokers. Moreover, exogenous antioxidant treatments might be used to improve oxidant/antioxidant homeostasis in lung injury.

References

1. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007. *J Allergy Clin Immunol.* 2007 Nov;120(5):S94–138.
2. Mims JW. Asthma: definitions and pathophysiology. *Int Forum Allergy Rhinol.* 2015 Sep;5(S1):S2–6.
3. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. *Eur Respir J.* 2013 Mar;41(3):716–26.
4. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med.* 2012 May;18(5):716–25.
5. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. *Drugs.* 2014 May 6;74(7):719–28.
6. Chung K, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. *European Respiratory ... Eur Respir J.* 1999;13(5).
7. Wener RRL, Bel EH. Severe refractory asthma: an update. *Eur Respir Rev.* 2013 Sep 1;22(129):227–35.
8. Proceedings of the ATS Workshop on Refractory Asthma. *Am J Respir Crit Care Med.* American Thoracic Society New York, NY; 2000 Dec;162(6):2341–51.
9. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol.* 2010 Nov;126(5):926–38.
10. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J.* 2014 Feb 1;43(2):343–73.
11. WAO white book on allergy : update 2013. 2013.
12. Akdis a. . (Eds), Agache I (Eds). *Global Atlas of Asthma.* Eur Acad

Allergy Clin Immunol. 2014;179.

13. European Lung white book [Internet]. [cited 2017 Mar 29]. Available from: <http://www.erswhitebook.org/chapters/adult-asthma/>
14. Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community: A large electronic database analysis. *Respir Med.* 2017;123:131–9.
15. Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. *J Allergy Clin Immunol.* 2015;135(4):896–902.
16. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract. BioMed Central;* 2017;3:1.
17. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health.* 2012 Dec 19;12(1):204.
18. Eisner MD, Yelin EH, Trupin L, Blanc PD. Asthma and smoking status in a population-based study of California adults. *Public Health Rep.* 2001 Mar 1;116(2):148–57.
19. Cerveri I, Cazzoletti L, Corsico AG, Marcon A, Niniano R, Grosso A, et al. The impact of cigarette smoking on asthma: a population-based international cohort study. *Int Arch Allergy Immunol.* 2012;158(2):175–83.
20. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. *J Allergy Clin Immunol.* 2007 Feb;119(2):405–13.
21. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J.* 2003 Sep;22(3):470–7.
22. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden M Lou, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. *Ann Allergy, Asthma Immunol.* 2004 Jan;92(1):32–9.

23. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. *Thorax*. 2010 Sep 1;65(9):787–94.
24. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. *Eur Respir J*. 2015 Sep 10;
25. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. *J Allergy Clin Immunol*. 2013 Apr;131(4):1008–16.
26. Plaschke PP, Janson C, Norrman E, Björnsson E, Ellbjär S, Järvholm B. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. *Am J Respir Crit Care Med*. 2000 Sep;162(3 Pt 1):920–4.
27. Rasmussen F, Siersted HC, Lambrechtsen J, Hansen HS, Hansen NC. Impact of airway lability, atopy, and tobacco smoking on the development of asthma-like symptoms in asymptomatic teenagers. *Chest*. 2000 May;117(5):1330–5.
28. Kim YK, Kim SH, Tak YJ, Jee YK, Lee BJ, Kim SH, et al. High prevalence of current asthma and active smoking effect among the elderly. *Clin Exp Allergy*. 2002 Dec;32(12):1706–12.
29. Torén K, Hermansson BA. Incidence rate of adult-onset asthma in relation to age, sex, atopy and smoking: a Swedish population-based study of 15813 adults. *Int J Tuberc Lung Dis*. 1999 Mar;3(3):192–7.
30. Vesterinen E, Kaprio J, Koskenvuo M. Prospective study of asthma in relation to smoking habits among 14,729 adults. *Thorax*. 1988 Jul;43(7):534–9.
31. Troisi RJ, Speizer FE, Rosner B, Trichopoulos D, Willett WC. Cigarette smoking and incidence of chronic bronchitis and asthma in women. *Chest*. 1995 Dec;108(6):1557–61.
32. Flodin U, Jönsson P, Ziegler J, Axelson O. An epidemiologic study of bronchial asthma and smoking. *Epidemiology*. 1995 Sep;6(5):503–5.
33. Chen Y, Dales R, Tang M, Krewski D. Sex-related interactive effect of smoking and household pets on asthma incidence. *Eur Respir J*. 2002

Nov;20(5):1162–6.

34. Piipari R, Jaakkola JJK, Jaakkola N, Jaakkola MS. Smoking and asthma in adults. *Eur Respir J*. 2004 Nov 1;24(5):734–9.
35. Polosa R, Knoke JD, Russo C, Piccillo G, Caponnetto P, Sarv  M, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. *J Allergy Clin Immunol*. 2008 Jun;121(6):1428–34.
36. WANG Z, CHEN C, NIU T, WU D, YANG J, WANG B, et al. Association of Asthma with Beta (2)-Adrenergic Receptor Gene Polymorphism and Cigarette Smoking. *Am J Respir Crit Care Med*. 2001 May;163(6):1404–9.
37. Raheison C, Baldi I, Tunon-De-Lara JM, Taytard A, Annesi-Maesano I. Asthma phenotypes according to the timing of smoking onset in young adults. *Int J Tuberc Lung Dis*. 2003 Jan;7(1):84–92.
38. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. *N Engl J Med*. 1998 Oct 22;339(17):1194–200.
39. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. *Chest*. 2007 Dec;132(6):1882–9.
40. Polosa R, Russo C, Caponnetto P, Bertino G, Sarv  M, Antic T, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. *Respir Res*. 2011 Jan;12:16.
41. Westerhof GA, Vollema EM, Weersink EJ, Reinartz SM, de Nijs SB, Bel EH. Predictors for the development of progressive severity in new-onset adult asthma. *J Allergy Clin Immunol*. 2014 Nov;134(5):1051–1056.e2.
42. Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, et al. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. *Int J Environ Res Public Health*. 2014 May;11(5):4965–77.
43. Tomlinson JEM, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. *Thorax*. 2005 Apr;60(4):282–7.

44. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. *Am J Respir Crit Care Med*. 2003 Dec 1;168(11):1308–11.
45. Livingston E, Chaudhuri R, McMahon AD, Fraser I, McSharry CP, Thomson NC. Systemic sensitivity to corticosteroids in smokers with asthma. *Eur Respir J*. 2007 Jan 27;29(1):64–71.
46. Kauppi P, Kupiainen H, Lindqvist A, Haahtela T, Laitinen T. Long-term smoking increases the need for acute care among asthma patients: a case control study. *BMC Pulm Med*. 2014 Jul 16;14(1):119.
47. Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. *J Infect*. 2013 Sep;67(3):169–84.
48. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. *Eur Respir J*. 2015 Sep 10;
49. Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. *J Allergy Clin Immunol*. 2017 Jun;139(6):1797–807.
50. Schleich F, Brusselle G, Louis R, Vandenas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). *Respir Med*. 2014 Dec;108(12):1723–32.
51. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. *Eur Respir J*. 2004 Nov 1;24(5):822–33.
52. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2001 May;163(6):1304–9.
53. Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. Airway inflammation in young marijuana and tobacco smokers. *Am J Respir Crit Care Med*. 1998 Mar;157(3 Pt 1):928–37.
54. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. *Eur Respir J*. 1996 Oct;9(10):1989–94.

55. Lams BE, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 1998 Nov;158(5 Pt 1):1518–23.
56. Boulet L-P, Lemièrè C, Archambault F, Carrier G, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. *Chest*. 2006 Mar;129(3):661–8.
57. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. *Chest*. 2001 Dec;120(6):1917–22.
58. Löffek S, Schilling O, Franzke C-W. Series ‘matrix metalloproteinases in lung health and disease’: Biological role of matrix metalloproteinases: a critical balance. *Eur Respir J*. 2011 Jul 1;38(1):191–208.
59. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S, et al. Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to disease severity. *J Allergy Clin Immunol*. 2012 Mar;129(3):655–663.e8.
60. Chaudhuri R, McSharry C, Brady J, Grierson C, Messow CM, Spears M, et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma. *Eur Respir J*. 2014 Oct 1;44(4):895–904.
61. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal*. 2014 Mar 1;20(7):1126–67.
62. Zuo L, Otenbaker NP, Rose BA, Salisbury KS. Molecular mechanisms of reactive oxygen species-related pulmonary inflammation and asthma. *Mol Immunol*. 2013 Nov;56(1–2):57–63.
63. Henricks PA, Nijkamp FP. Reactive oxygen species as mediators in asthma. *Pulm Pharmacol Ther*. 2001 Jan;14(6):409–20.
64. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. *Eur J Pharmacol*. 2006 Mar 8;533(1–3):222–39.
65. Kinnula VL. Focus on antioxidant enzymes and antioxidant strategies in

- smoking related airway diseases. *Thorax*. 2005 Aug;60(8):693–700.
66. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev*. 2007 Jan;87(1):245–313.
 67. Lee I-T, Yang C-M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. *Biochem Pharmacol*. 2012 Sep 1;84(5):581–90.
 68. Holguin F. Oxidative stress in airway diseases. *Ann Am Thorac Soc*. 2013 Dec;10 Suppl:S150-7.
 69. Kinnula VL, Lehtonen S, Koistinen P, Kakko S, Savolainen M, Kere J, et al. Two functional variants of the superoxide dismutase genes in Finnish families with asthma. *Thorax*. 2004 Feb;59(2):116–9.
 70. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. *Am J Respir Crit Care Med*. 2003 Jun 15;167(12):1600–19.
 71. Vlahos R, Bozinovski S. Glutathione peroxidase-1 as a novel therapeutic target for COPD. *Redox Rep*. 2013 Jan;18(4):142–9.
 72. Dweik RA. Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly! *Thorax*. 2005 Apr;60(4):265–7.
 73. Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update. *Trends Immunol*. 2015 Feb;36(3):161–78.
 74. Batra J, Chatterjee R, Ghosh B. Inducible nitric oxide synthase (iNOS): role in asthma pathogenesis. *Indian J Biochem Biophys*. 2007 Oct;44(5):303–9.
 75. Mattila JT, Thomas AC. Nitric oxide synthase: non-canonical expression patterns. *Front Immunol*. 2014 Jan;5:478.
 76. Colombo G, Clerici M, Giustarini D, Portinaro NM, Aldini G, Rossi R, et al. Pathophysiology of tobacco smoke exposure: Recent insights from comparative and redox proteomics. *Mass Spectrom Rev*. 2014 May;33(3):183–218.
 77. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects

- with other respirable particles. *Int J Environ Res Public Health*. 2009 Feb;6(2):445–62.
78. Rom O, Kaisari S, Aizenbud D, Reznick AZ. Identification of possible cigarette smoke constituents responsible for muscle catabolism. *J Muscle Res Cell Motil*. 2012 Aug;33(3–4):199–208.
 79. Home | U-BIOPRED [Internet]. [cited 2016 Feb 23]. Available from: <http://www.europeanlung.org/en/projects-and-research/projects/u-biopred/home>
 80. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax*. 2011 Oct 1;66(10):910–7.
 81. Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med*. American Thoracic Society; 2009 Jul 1;180(1):59–99.
 82. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005 Aug;26(2):319–38.
 83. Balgoma D, Larsson J, Rokach J, Lawson JA, Daham K, Dahlén B, et al. Quantification of lipid mediator metabolites in human urine from asthma patients by electrospray ionization mass spectrometry: controlling matrix effects. *Anal Chem*. American Chemical Society; 2013 Aug 20;85(16):7866–74.
 84. Ng DSW, Liao W, Tan WSD, Chan TK, Loh XY, Wong WSF. Anti-malarial drug artesunate protects against cigarette smoke-induced lung injury in mice. *Phytomedicine*. 2014 Oct 15;21(12):1638–44.
 85. Ho WE, Cheng C, Peh HY, Xu F, Tannenbaum SR, Ong CN, et al. Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma. *Free Radic Biol Med*. 2012 Aug 1;53(3):498–507.
 86. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J*. 2006 Jul;28(1):219–42.

87. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflammation and asthma. *Eur Respir J.* 2003 Jan;21(1):177–86.
88. Mak JCW, Ho SP, Ho ASS, Law BKW, Cheung AHK, Ho JCM, et al. Sustained elevation of systemic oxidative stress and inflammation in exacerbation and remission of asthma. *ISRN Allergy.* 2013 Jan;2013:561831.
89. Cheng S-E, Lee I-T, Lin C-C, Kou YR, Yang C-M. Cigarette smoke particle-phase extract induces HO-1 expression in human tracheal smooth muscle cells: role of the c-Src/NADPH oxidase/MAPK/Nrf2 signaling pathway. *Free Radic Biol Med.* 2010 May 15;48(10):1410–22.
90. Yao H, Yang S-R, Kode A, Rajendrasozhan S, Caito S, Adenuga D, et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. *Biochem Soc Trans.* 2007 Nov;35(Pt 5):1151–5.
91. Bruijnzeel PLB, Uddin M, Koenderman L. Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype? *J Leukoc Biol.* 2015 Oct 1;98(4):549–56.
92. Xue J, Schmidt S V, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity.* 2014 Feb 20;40(2):274–88.
93. Voraphani N, Gladwin MT, Contreras AU, Kaminski N, Tedrow JR, Milosevic J, et al. An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma. *Mucosal Immunol.* 2014 Sep;7(5):1175–85.
94. Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. *Clin Exp Allergy.* 2012 May;42(5):760–8.
95. Roos AB, Mori M, Grönneberg R, Österlund C, Claesson H-E, Wahlström J, et al. Elevated exhaled nitric oxide in allergen-provoked asthma is associated with airway epithelial iNOS. *PLoS One.* 2014 Jan;9(2):e90018.
96. Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE. NOS2 regulation of NF-kappaB by S-nitrosylation of p65. *J Biol Chem.* 2007 Oct

19;282(42):30667–72.

97. Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. *Thorax*. 2004 Sep;59(9):757–60.
98. Horváth I, Donnelly LE, Kiss A, Balint B, Kharitonov SA, Barnes PJ. Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. *Respiration*. 2004;71(5):463–8.
99. Comhair SAA, Ricci KS, Arroliga M, Lara AR, Dweik RA, Song W, et al. Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. *Am J Respir Crit Care Med*. 2005 Aug 1;172(3):306–13.
100. Comhair SAA, Xu W, Ghosh S, Thunnissen FBJM, Almasan A, Calhoun WJ, et al. Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity. *Am J Pathol*. 2005 Mar;166(3):663–74.
101. Marklund SL. Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. *J Biol Chem*. 1992 Apr 5;267(10):6696–701.
102. Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. *Am J Pathol*. 1998 Jan;152(1):269–78.
103. York GK, Peirce TH, Schwartz LW, Cross CE. Stimulation by cigarette smoke of glutathione peroxidase system enzyme activities in rat lung. *Arch Environ Health*. 1976 Jan;31(6):286–90.
104. Jenifer HD, Bholá S, Kalburgi V, Warad S, Kokatnur VM. The influence of cigarette smoking on blood and salivary super oxide dismutase enzyme levels among smokers and nonsmokers—A cross sectional study. *J Tradit Complement Med*. 2015 Apr;5(2):100–5.
105. Hoffmann RF, Zarrintan S, Brandenburg SM, Kol A, de Bruin HG, Jafari S, et al. Prolonged cigarette smoke exposure alters mitochondrial structure and function in airway epithelial cells. *Respir Res*. 2013 Jan;14:97.
106. Betsuyaku T, Fuke S, Inomata T, Kaga K, Morikawa T, Odajima N, et al. Bronchiolar epithelial catalase is diminished in smokers with mild

COPD. Eur Respir J. 2013 Jul;42(1):42–53.